CLOs on the Move

Metacrine

www.metacrine.com

 
We are a clinical-stage biopharmaceutical company focused on discovering and developing best-in-class therapies for patients with liver and gastrointestinal, or GI, diseases. Since our founding in 2014, we have invested in building a foundation of chemistry and biology expertise to drive innovative drug discovery and development. We believe these internal capabilities allow us to gain insights into disease targets and mechanisms and more quickly and purposefully design therapies with characteristics that we view as key to safety and efficacy. With this systematic approach, we have designed novel, proprietary farnesoid X receptor (FXR) clinical product candidates arising from a unique chemical ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.metacrine.com
  • 3985 Sorrento Valley Boulevard Suite C
    San Diego, CA USA 92121
  • Phone: 858.369.7800

Executives

Name Title Contact Details
Catherine Lee
Senior Vice President and General Counsel Profile

Similar Companies

Interpace Biosciences

Interpace Biosciences is a company that provides molecular and related first line diagnostic tests for evaluating risk of cancer, as well as specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted...

TriSalus Life Sciences

TriSalus Life Sciences is dedicated to improving patient outcomes in pancreatic and other highly intractable solid tumors. TriSalus Infusion Systems, powered by the proprietary Pressure-Enabled Drug Delivery (PEDD) approach with SmartValve technology have the potential to improve the delivery and distribution of diagnostic agents, therapeutics, and immuno-stimulants into the tumor vasculature.

Bioporto

BioPorto s flagship product, The NGAL Test™, aids in the risk assessment of AKI in critically ill patients. CE marked for IVD use in select regions.

Lion Biotechnologies

Lion Biotechnologies (LBIO) is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). Under a collaborative research and development agreement with Dr. Steven A. Rosenberg at the National Cancer Institute, we are investigating our our lead product candidate, LN-144, in the treatment of stage 4 metastatic melanoma. In clinical trials, LN-144 has demonstrated curative potential in patients with metastatic melanoma, and it may also be applicable to a wide range of other solid tumors. As we continue advancing our current clinical programs in collaboration with NCI, Moffitt Cancer Center and MD Anderson, we are also developing next-generation TIL products and an optimized manufacturing process that will enable the production of highly potent, engineered cells at a significantly reduced cost. With unique and versatile technology, promising clinical programs, strong intellectual property, high-profile collaborations and seasoned leadership, Lion is committed to elevating hope and treatment standards for patients, while creating exceptional value for its shareholders.

CereVasc

The CereVasc eShunt™ device is intended to improve patient outcomes and redefine the treatment of communicating hydrocephalus.